Survival Estimation, Prognostic Factors Evaluation, and Prognostic Prediction Nomogram Construction of Breast Cancer Patients with Bone Metastasis in the Department of Bone and Soft Tissue Tumor: A Single Center Experience of 8 Years in Tianjin, China
Table 2
Univariate Cox proportional hazard regression model for analyzing associated factors in the construction cohort.
Subject characteristics
B
SE
Wald
value
HR
HR 95% CI
Age
18–45
11.006
0.004
1.00
Ref
46–55
0.169
0.176
0.916
0.338
1.18
0.84–1.67
>55
0.590
0.180
10.675
0.001
1.80
1.27–2.57
Marital status
Married
1.00
Ref
Unmarried
0.230
0.343
0.449
0.503
1.26
0.64–2.46
History of smoking
Yes
1.00
Ref
No
0.172
0.364
0.224
0.636
1.19
0.58–2.43
Alcohol consumption
Yes
1.00
Ref
No
0.182
0.342
0.281
0.596
1.20
0.61–2.35
Menstrual status
Menstruation
1.00
Ref
Menopause
−0.211
0.161
1.717
0.190
0.81
0.59–1.11
History of abortion
No
1.00
Ref
Yes
0.010
0.157
0.004
0.952
1.01
0.74–1.38
Family history of tumor
Yes
1.00
Ref
No
−0.079
0.171
0.212
0.645
0.92
0.66–1.29
ABO blood type
A type
6.885
0.076
1.00
Ref
B type
0.092
0.188
0.240
0.624
1.10
0.76–1.59
AB type
0.558
0.235
5.656
0.017
1.75
1.10–2.77
O type
−0.002
0.204
0
0.994
1.00
0.67–1.49
HGB
115–150 g/L
2.906
0.234
1.00
Ref
<115 g/L
0.098
0.193
0.258
0.611
1.10
0.76–1.61
>150 g/L
0.758
0.457
2.758
0.097
2.14
0.87–5.22
CA153
0–25 U/ml
1.00
Ref
>25 U/ml
−0.342
0.158
4.684
0.030
0.71
0.52–0.97
CEA
0–5 ng/ml
1.00
Ref
>5 ng/ml
−0.142
0.146
0.946
0.331
0.87
0.65–1.16
ALP
50–135 U/L
7.375
0.025
1.00
Ref
<50 U/L
0.118
0.267
0.197
0.657
1.13
0.67–1.90
>135 U/L
0.451
0.166
7.373
0.007
1.57
1.13–2.18
Serum calcium
2.10–2.55 mmol/L
1.613
0.446
1.00
Ref
<2.10 mmol/L
0.185
0.232
0.636
0.425
1.20
0.76–1.89
>2.55 mmol/L
0.207
0.185
1.251
0.263
1.23
0.86–1.77
Pathology
Ductal carcinoma
1.00
Ref
Others
0.227
0.152
2.240
0.134
1.26
0.93–1.69
Grade
I-II
1.00
Ref
III
0.470
0.160
8.654
0.003
1.60
1.17–2.19
Tumor size
<2 cm
0.816
0.665
1.00
Ref
2–5 cm
0.073
0.165
0.196
0.658
1.08
0.78–1.49
>5 cm
0.214
0.238
0.814
0.367
1.24
0.78–1.97
Lymph node metastasis
Yes
1.00
Ref
No
−0.459
0.191
5.766
0.016
0.63
0.44–0.92
ER status
Positive
1.00
Ref
Negative
0.330
0.154
4.615
0.032
1.39
1.03–1.88
PR status
Positive
1.00
Ref
Negative
0.396
0.146
7.390
0.007
1.49
1.12–1.98
Her-2 status
Positive
1.00
Ref
Negative
−0.411
0.172
5.735
0.017
0.66
0.47–0.93
Ki-67 status
Positive
1.00
Ref
Negative
0.522
0.176
8.791
0.003
1.69
1.19–2.38
Surgery for BC
Yes
1.00
Ref
No
1.372
0.181
57.553
<0.001
3.94
2.77–5.62
Chemotherapy
No
1.00
Ref
Yes
−0.802
0.344
5.430
0.020
0.45
0.23–0.88
Radiotherapy
No
1.00
Ref
Yes
−0.036
0.150
0.058
0.810
0.97
0.72–1.30
Endocrinotherapy
No
1.00
Ref
Yes
−0.473
0.147
10.35
0.001
0.62
0.47–0.83
Targeted therapy
No
1.00
Ref
Yes
0.211
0.211
0.998
0.318
1.24
0.82–1.87
Time of BM
SBM
1.00
Ref
MBM
−1.104
0.163
45.613
<0.001
0.33
0.24–0.46
Radiotherapy for BM
No
1.00
Ref
Yes
0.085
0.186
0.208
0.649
1.09
0.76–1.57
Pathological fracture
No
1.00
Ref
Yes
0.300
0.263
1.304
0.254
1.35
0.81–2.26
Spinal cord compression
No
1.00
Ref
Yes
−0.066
0.416
0.026
0.873
0.94
0.41–2.11
Surgery for BM
No
1.00
Ref
Yes
0.077
0.455
0.029
0.865
1.08
0.44–2.63
Performance of BPs
No
1.00
Ref
Yes
−0.382
0.166
5.288
0.021
0.68
0.49–0.95
Liver metastasis
No
1.00
Ref
Yes
0.469
0.147
10.140
0.001
1.60
1.2–2.13
Brain metastasis
No
1.00
Ref
Yes
0.355
0.212
2.807
0.094
1.43
0.94–2.16
Lung metastasis
No
1.00
Ref
Yes
−0.311
0.150
4.335
0.037
0.73
0.55–0.98
Other organs metastasis
No
1.00
Ref
Yes
−0.366
0.179
4.182
0.041
0.69
0.49–0.99
HGB: hemoglobin; CA153: carbohydrate antigen 153; CEA: carcinoembryonic antigen; ALP: alkaline phosphatase; ER: estrogen receptor; PR: progesterone receptor; Her-2: human epidermal growth factor receptor 2; BC: breast cancer; BM: bone metastasis; SBM: synchronous bone metastasis; MBM: metachronous bone metastasis; BPs: bisphosphonates.
